-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
1-2-1 Meetings/Networking Break
-
Bi/Multispecifics
Can bi- or multi-specifics approaches revitalize known targets? Balancing the target affinities and
...
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
Drinks-Canape Reception
-
Emerging Technologies
Disease complexity, e.g. causality, heterogeneity, targetability, etc Drug discovery efficiency, e.g
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Agonistic antibodies to checkpoint inhibitors – how to select the best epitope and achieve engagemen
...
-
Target Selection
What does a protein engineer bring to the table when selecting therapeutic targets? What are new or
...
-
Emerging Technologies
The computational development of antibodies is an emerging industry that has become feasible thanks
...
-
Bi/Multispecifics
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr
...
-
Formats & Scaffolds
Biologics have become the top-selling class of therapeutics that continue to grow as new drugs are a
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
VHHs, the variable domains of camelid heavy chain-only antibodies, are gaining significant attention
...
-
Target Selection
The PioneerTM Antibody Discovery Platform is Bio-Rad’s new service for biotherapeutic lead generatio
...
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr
...
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
Antibody fragments like Fab, ScFv, and VHH are emerging stars in antibody drug development, utilized
...
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
1-2-1 Meetings/Networking Break
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
Afternoon refreshments
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
Registration
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
1-2-1 Meetings/Networking Break
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
Networking Lunch
-
Emerging Technologies
Antibody discovery vs complex antigens that cannot be easily purified remains a challenge. Does the
...
-
Bi/Multispecifics
Common Light Chain discovery approaches, advantages, and limitations Single Domain Antibodies: what
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Integrated antibody discovery mindset based on biotherapeutic MOA is critical. How to choose lead id
...
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
1-2-1 Meetings/Networking Break
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
Morning refreshments
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
1-2-1 Meetings/Networking Break
-
Emerging Technologies
-
Bi/Multispecifics
-
Lead Identification & Optimization
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Target Selection
-
-
Bi/Multispecifics
-
Emerging Technologies
-
Formats & Scaffolds
-
Lead Identification & Optimization
-
Target Selection
)
The computational development of antibodies is an emerging industry that has become feasible thanks ...![Poster Presentation: Antibody Discovery Dead Ends and New Approaches: The Power of Polyclonal Sequencing [Emerging Technologies Topic]](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/Rapid-Novor.png/fit-in/500x9999/filters:no_upscale())
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr ...![Poster Presentation: AlivaMab' Platforms for Discovery and Engineering for Bispecifics and Advanced Modalities Jane Seagal, Vice President, Antibody Discovery, Ablexis and AlivaMab Discovery Services [Bi/ Multi Specifics Topic]](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/experts/Ablexis-Alivamab-Stacked-Logo.png/fit-in/500x9999/filters:no_upscale())
Biologics have become the top-selling class of therapeutics that continue to grow as new drugs are a ...Poster Presentation by Ablexis and AlivaMab Discovery Services)
VHHs, the variable domains of camelid heavy chain-only antibodies, are gaining significant attention ...Poster Presentation by Immunoprecise Antibodies![Poster Presentation: Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform [Lead Identification & Optimization Topic]](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/partners/Bio-Rad.png/fit-in/500x9999/filters:no_upscale())
The PioneerTM Antibody Discovery Platform is Bio-Rad’s new service for biotherapeutic lead generatio ...)
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr ...)
Antibody fragments like Fab, ScFv, and VHH are emerging stars in antibody drug development, utilized ...)
Antibody discovery vs complex antigens that cannot be easily purified remains a challenge. Does the ...
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)